%0 Generic
%T Response by Lam and Gerstein to Letter Regarding Article, “Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial”
%A Lam, Carolyn S.P.
%A Gerstein, Hertzel C.
%I Ovid Technologies (Wolters Kluwer Health)
%@ 0009-7322
%@ 1524-4539
%K Physiology (medical)
%K Cardiology and Cardiovascular Medicine
%D 2022
%C Ovid Technologies (Wolters Kluwer Health)
%U http://slubdd.de/katalog?TN_libero_mab2
Download citation